Why was this year's flu vaccine less effective?

The vaccine was designed to target a different H3N2 strain, but a new subclade (K) emerged and became dominant. This mismatch reduced the vaccine's effectiveness to around 25-30% in adults.

How does this season compare to previous flu seasons?

This season had fewer illnesses and hospitalizations than last year's record-high numbers but still resulted in 22,000 deaths. New York City reported its most intense flu season in 20 years.

Will next year's flu vaccine be better?

Yes, the WHO and FDA have recommended that next year's vaccine target the problematic H3N2 subclade K, which should improve its effectiveness.

Flu Vaccine Effectiveness Hits Decade Low in U.S., CDC Reports

As the 2023-2024 U.S. flu season nears its end, health officials have confirmed what many doctors feared: this year's flu vaccine performed poorly, with effectiveness rates among the lowest in over a decade. The Centers for Disease Control and Prevention (CDC) reported that vaccines were only 25% to 30% effective in preventing flu illnesses severe enough to require medical attention in adults, while children saw slightly better protection at around 40%. Experts attribute the weak performance to a new H3N2 subclade that emerged unexpectedly, catching vaccine developers off guard.

This season's flu vaccine effectiveness (25-30% for adults) ranks among the lowest in the past two decades.
A new H3N2 subclade (K) dominated infections, which the vaccine was not designed to target.
Despite low effectiveness, vaccination reduced severe outcomes, with 85% of pediatric flu deaths occurring in unvaccinated children.
CDC estimates 27 million flu illnesses, 350,000 hospitalizations, and 22,000 deaths this season.
Next year's vaccine will target the problematic H3N2 subclade, following WHO recommendations.

Why This Year's Flu Vaccine Performed Poorly

The primary reason for this season's weak vaccine performance was a mismatch between the circulating influenza strains and those included in the vaccine. Each year, global health authorities predict which flu strains will dominate and design vaccines accordingly. However, this year's dominant strain—a new subclade of H3N2 known as K—was not adequately represented in the vaccine formulation.

The Role of H3N2 Subclade K

H3N2 viruses are notorious for their ability to mutate rapidly, making them particularly challenging to target with vaccines. Subclade K, which emerged this season, spread more efficiently than previous variants but did not necessarily cause more severe illness. Dr. William Schaffner, a vaccine expert at Vanderbilt University, explained that while the vaccine was designed to protect against a different H3N2 variant, the new subclade's rapid spread overwhelmed its limited effectiveness.

The Impact of Low Vaccination Rates and Severe Outcomes

While the vaccine's poor performance contributed to widespread flu cases, low vaccination rates also played a role. This season saw adult vaccination rates rise slightly to 46.5%, up from previous years, but pediatric vaccination remained stagnant at around 48%. Tragically, at least 101 children died from flu-related complications this season, with 85% of those cases occurring in unvaccinated children. Dr. Schaffner emphasized that even with low effectiveness, vaccination significantly reduces the risk of severe illness and death.

How This Season Compares to Previous Years

The CDC estimates that this season resulted in at least 27 million flu illnesses, 350,000 hospitalizations, and 22,000 deaths. While the number of illnesses and hospitalizations was lower than last year's record-high 40 million cases and 520,000 hospitalizations, the death toll remained alarmingly consistent. New York City health officials described this season as the most intense in two decades, with hospitals overwhelmed by flu patients in late December and early January.

Preparing for Next Year's Flu Season

In response to this season's challenges, the World Health Organization (WHO) has already recommended that next year's flu vaccines target the problematic H3N2 subclade K. The U.S. Food and Drug Administration (FDA) endorsed these recommendations this week, ensuring that vaccine manufacturers will adjust their formulations accordingly. Experts hope this proactive approach will improve vaccine effectiveness for the 2024-2025 flu season.

Frequently Asked Questions

Why was this year's flu vaccine less effective?: The vaccine was designed to target a different H3N2 strain, but a new subclade (K) emerged and became dominant. This mismatch reduced the vaccine's effectiveness to around 25-30% in adults.
How does this season compare to previous flu seasons?: This season had fewer illnesses and hospitalizations than last year's record-high numbers but still resulted in 22,000 deaths. New York City reported its most intense flu season in 20 years.
Will next year's flu vaccine be better?: Yes, the WHO and FDA have recommended that next year's vaccine target the problematic H3N2 subclade K, which should improve its effectiveness.